Eurofins Optimed Clinical Research
and
Spaulding Clinical Research
announced a joint partnership agreement. This partnership leverages the strengths of both companies and facilitates collaboration on integrated clinical services to engage pharmaceutical clients who demand a global footprint.
"The culture of excellence and research facilities designed to execute high-quality studies was very impressive to our team. We felt immediately comfortable with the Optimed clinical team and witnessed their efficient execution of studies," states Daniel Selness, General Manager and Senior Vice President of Operations. "We were very impressed that Spaulding achieved ISO certification, which is not common among US clinical research facilities. Their systems approach with Electronic Data Capture is something that we have been looking to implement, so the partnership will allow us to consider how to collaborate more closely as these systems are put in place," states Yves Donazzolo, MD, CEO and President of Optimed.
Eurofins Optimed and Spaulding Clinical offer a full range of global services to the Pharmaceutical industry and Biotechnology companies from study design through study execution/conduct, data management, statistical analysis, and medical writing. Both companies excel in TQT, first-in-human, multiple rising dose, bioavailability/bioequivalence, drug interaction, food effect studies and Proof-Of-Concept studies in patients.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Issues Complete Response Letter to Replimune for RP1 Combination Therapy in Advanced Melanoma
July 22nd 2025The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (NCT03767348) trial in advanced melanoma was not an adequate, well-controlled study and that its heterogeneous patient population limited interpretability, preventing approval in its current form.